Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20124978 | 0.84 | DRD2 (0.35) | CHRNB2CHRNA4DRD2DRD1PDK2 | |
| SCHEMBL20125119 | 0.84 | DRD2 (0.35) | CHRNB2CHRNA4DRD2DRD1PDK2 | |
| SCHEMBL23938075 | 0.72 | CHRNB2 (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL23416751 | 0.67 | — | — | |
| SCHEMBL13199592 | 0.66 | CA1 (0.36) | CHRNB2CHRNA4DRD2DRD1PDK2 | |
| SCHEMBL7914307 | 0.66 | CA1 (0.36) | CHRNB2CHRNA4DRD2DRD1PDK2 | |
| SCHEMBL7921085 | 0.63 | CCR1 (0.32) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL7914306 | 0.62 | NNMT (0.58) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL21729487 | 0.62 | NNMT (0.58) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL13330178 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |